Rockwell Licenses Commercialization Rights

 

Wanbang Biopharmaceutical will commercialize Rockwell Medical’s Triferic® and Calcitriol treatments in China, under an exclusive license agreement.

The agreement was disclosed today by Rockwell, which could generate up to $39 million in upfront and milestone payments from Wanbang. Rockwell will receive ongoing earnings from product sales of Triferic and Calcitriol, and other additional Triferic therapeutic indications.

Subscribe to get the latest news